UroGen Pharma Ltd. (URGN)

UroGen Pharma Revenue

In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth. Revenue in the quarter ending December 31, 2023 was $23.53M with 30.06% year-over-year growth.

• Revenue (ttm): $82.71M
• Revenue Growth: +28.52%
• P/S Ratio: 5.84
• Revenue / Employee: $417,742
• Employees: 198
• Market Cap: 482.83M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	82.71M	18.36M	28.52%
Dec 31, 2022	64.36M	16.32M	33.96%
Dec 31, 2021	48.04M	36.24M	307.17%
Dec 31, 2020	11.80M	11.78M	65,450.00%
Dec 31, 2019	18.00K	-1.11M	-98.40%
Dec 31, 2018	1.13M	-7.03M	-86.17%
Dec 31, 2017	8.16M	-9.37M	-53.46%
Dec 31, 2016	17.53M	-	-
Dec 31, 2015	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.